ArticleEuropean radiology2025
Current use of percutaneous ablation in renal tumors: an analysis of the registry of the German Society for Interventional Radiology and Minimally Invasive Therapy.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Safety and Effectiveness in 400 Image-Guided Spleen Biopsies from the DeGIR Registry.Cardiovascular and interventional radiology · 2026Article
- Partial Nephrectomy Versus Thermal Ablation for Cystic Renal Tumors: A Registry-Based, Propensity Score Matched Analysis (UroCCR n°177).Cardiovascular and interventional radiology · 2026Article
- Image-guided percutaneous ablation techniques for the treatment of renal cell carcinoma: a primer for radiologists.Abdominal radiology (New York) · 2026Review
- Reply to the Letter to the Editor: Current use of percutaneous ablation in renal tumors-an analysis of the registry of the German Society for Interventional Radiology and Minimally Invasive Therapy.European radiology · 2026Article
- Letter to the Editor: Current use of percutaneous ablation in renal tumors-an analysis of the registry of the German Society for Interventional Radiology and Minimally Invasive Therapy.European radiology · 2026Article
- Adjunctive Techniques for Optimizing Percutaneous CT-Guided Cryoablation of Renal Tumours.Cancers · 2026Review
- Effectiveness and Safety of Image-Guided Renal Biopsies: Insights from 5,235 Procedures in the German Society for Interventional Radiology and Minimally Invasive Therapy (DeGIR) Registry.Cardiovascular and interventional radiology · 2026Article
- Association Between Renal Cell Cancer and Chronic Kidney Disease: An Update on a Never-Healing Wound.Biomedicines · 2025Review
- Reassessment of T1a cutoff for kidney cancer in the robotic era.Journal of robotic surgery · 2025Article
- Not just a picture of a changing treatment landscape: what registry data from Germany add to our knowledge about thermal ablation for kidney tumors.European radiology · 2025Article
- Real-world safety of irreversible electroporation therapy for tumors with nanoknife: MAUDE database analysis.BMC surgery · 2025Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the success and complications of thermal ablation (TA) based on the voluntary, prospective registry of the German Society for Interventional Radiology and Minimally Invasive Therapy (DeGIR) with 303 participating centers from Germany, Austria, and Switzerland. MATERIALS AND
methodsRegistry data from 2018 until 2023 of 1102 patients with small renal tumors (age: 72.5 ± 11.6 years; female: 33.6%, 370/1102) were analyzed. Hospitals with ≥ 20 TAs were considered high-volume centers. Technical success and complication rates between different parameters were compared using the chi-square or Fisher's exact test, p < 0.05 was considered statistically significant.
resultsPatients were most frequently treated with radiofrequency ablation (RFA, 43.6%, 481/1102), then microwave ablation (MWA, 41.9%, 462/1102) or cryoablation (13.3%, 147/1102). Technical success for heat-based TA (RFA&MWA) was 94.3% (893/947), for cryoablation 97.3% (143/147). RFA&MWA was significantly more successful in lesions ≤ 3 cm (96.1%, 567/590) compared to 3-4 cm lesions (89.8%, 97/108; p = 0.005). In patients treated with cryoablation, no significant differences between sizes could be found (≤ 3 cm: 97.9%, 94/96; 3-4 cm: 85.7%, 12/14; p = 0.078). Complication rate was significantly higher in RFA&MWA of lesions 3-4 cm compared to ≤ 3 cm (≤ 3 cm: 3.9%, 23/590; 3-4 cm: 11.1%, 12/108, p = 0.002), while no significant differences were seen regarding cryoablation (≤ 3 cm: 1.0%, 1/96; 3-4 cm: 0.0%, 0/14; p = 1.000).
conclusionsIn this exploratory analysis of the DeGIR registry, percutaneous TA of small renal masses is technically feasible with low complication rates. Heat-based TAs seem to have lower success rates and higher complication rates in larger tumors. Cryoablation could potentially be a safe alternative for 3- to 4-cm-sized tumors. KEY POINTS: Question How effective is renal thermal ablation (TA) in terms of treatment success and complication rates? Findings In contrast to cryoablation, heat-based thermal ablation has lower success and higher complication rates in tumors measuring 3-4 cm compared to tumors < 3 cm. Clinical relevance Thermal ablation is not influenced by the need for additional techniques such as cooling, protective organ displacement, or temporary vessel occlusion. For small renal tumors, TA is an effective and safe treatment option. Cryoablation could be beneficial in larger tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.